Literature DB >> 11991878

Assessment of microvascular leakage via sputum induction: the role of substance P and neurokinin A in patients with asthma.

Elizabeth L J Van Rensen1, Pieter S Hiemstra, Klaus F Rabe, Peter J Sterk.   

Abstract

Microvascular leakage is an important feature of inflammation. However, the assessment of vascular leakage has seldom been used to monitor airway inflammation in asthma. The aim of this study was to determine the effect of inhaled substance P, a potent neurokinin 1 (NK1) agonist and mediator of plasma extravasation, on markers of microvascular leakage in induced sputum from patients with asthma. In a crossover study, sputum was induced before and 30 minutes after inhalation of substance P or neurokinin A (as control) by 12 subjects with atopic and mild, steroid-naive asthma. The levels of alpha2-macroglobulin, ceruloplasmin, albumin, and fibrinogen were determined in induced sputum as markers of leakage. Substance P induced a significant increase in the levels of alpha2-macroglobulin, ceruloplasmin, and albumin in induced sputum (median fold change, 3.1, 2.2, and 2.9, respectively) (p < 0.013), whereas inhaled neurokinin A was not able to induce significant changes (p > 0.31). The increase in sputum leakage markers was not associated with the cumulative dose of substance P (p > 0.12). These results indicate that NK1 receptor stimulation causes a rapid increase in microvascular leakage as shown in induced sputum in patients with asthma. This investigational model of "dual induction" (first leakage, then sputum) may therefore be useful to test the antiexudative effect of newly develop drugs, such as NK1 antagonists.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11991878     DOI: 10.1164/rccm.2110092

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  8 in total

1.  Sampling airway surface liquid: non-volatiles in the exhaled breath condensate.

Authors:  Terry M Dwyer
Journal:  Lung       Date:  2004       Impact factor: 2.584

2.  Increased tachykinin levels in induced sputum from asthmatic and cough patients with acid reflux.

Authors:  Robert N Patterson; Brian T Johnston; Joy E S Ardill; Liam G Heaney; Lorcan P A McGarvey
Journal:  Thorax       Date:  2007-01-24       Impact factor: 9.139

Review 3.  Human umbilical cord blood-derived mast cells: a unique model for the study of neuro-immuno-endocrine interactions.

Authors:  T C Theoharides; D Kempuraj; M Tagen; M Vasiadi; C L Cetrulo
Journal:  Stem Cell Rev       Date:  2006       Impact factor: 5.739

4.  Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD.

Authors:  Diana C Grootendorst; Stefanie A Gauw; Renate M Verhoosel; Peter J Sterk; Jeannette J Hospers; Dirk Bredenbröker; Thomas D Bethke; Pieter S Hiemstra; Klaus F Rabe
Journal:  Thorax       Date:  2007-06-15       Impact factor: 9.139

5.  Disodium cromoglycate inhibits capsaicin-induced eosinophil infiltration of conjunctiva independent of mast cells.

Authors:  Nobuyuki Ebihara; Motoaki Nishikawa; Akira Murakami
Journal:  Jpn J Ophthalmol       Date:  2006 May-Jun       Impact factor: 2.211

Review 6.  Airways exudation of plasma macromolecules: Innate defense, epithelial regeneration, and asthma.

Authors:  Carl Persson
Journal:  J Allergy Clin Immunol       Date:  2018-08-29       Impact factor: 10.793

7.  Neutrophil-derived heparin binding protein triggers vascular leakage and synergizes with myeloperoxidase at the early stage of severe burns (With video).

Authors:  Lu Liu; Yiming Shao; Yixuan Zhang; Yunxi Yang; Jiamin Huang; Linbin Li; Ran Sun; Yuying Zhou; Yicheng Su; Bingwei Sun
Journal:  Burns Trauma       Date:  2021-09-17

8.  Sputum mediator profiling and relationship to airway wall geometry imaging in severe asthma.

Authors:  Dhananjay Desai; Sumit Gupta; Salman Siddiqui; Amisha Singapuri; William Monteiro; James Entwisle; Sudha Visvanathan; Harsukh Parmar; Radhika Kajekar; Christopher E Brightling
Journal:  Respir Res       Date:  2013-02-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.